Long-term TNF-alpha therapy for preserving beta cell function in new onset type 1 diabetes: a case report.

ABSTRACT:

Background

Type 1 diabetes mellitus (T1D) is an autoimmune disease caused by destruction of pancreatic islet beta-cells. There is significant residual beta-cell function, measured through circulating C-peptide, present at the time of T1D diagnosis but this subsequently decreases with time. Higher residual beta-cell function at diagnosis associates with better glycaemic control and less glucose variability, and later in the disease course with less hypoglycaemia, lower glucose variability and fewer microvascular complications. There is therefore value in preserving residual beta cell function in new onset T1D Immunotherapeutic agents can protect residual beta-cell function in type 1 diabetes. However, clinical trials of such agents, whilst demonstrating C-peptide preservation in sho

SUBMITTER: Rao A 

PROVIDER: S-EPMC11386087 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature